IL6 and cancer: Following our observation of increased CD4+ T-cells in miR-122 high patients, the circulating plasma levels of the chemokine CCL17 (TARC) and the cytokine IL-6 were measured as both are known to be part of the immune–tumor interaction and contribute to the cancer-promoting effects of inflammation and immune modulation.